Department of Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan City, Shanxi Province, China.
Department of Respiratory Medicine, Xinzhou People's Hospital, Xinzhou City, Shanxi Province, China.
Immun Inflamm Dis. 2023 Oct;11(10):e1041. doi: 10.1002/iid3.1041.
To investigate the clinical efficacy of plasma exchange (PE) with or without prednisone and hydroxychloroquine (HCQ) for the treatment of systemic lupus erythematosus (SLE) during pregnancy.
The clinical characteristics of 14 pregnant women with SLE admitted to our hospital were retrospectively analyzed, including 7 only treated with prednisone and HCQ (non-PE group) as well as 7 combined PE (PE group). The delivery situations of 14 patients were recorded. Data like erythrocyte sedimentation rate (ESR), urine protein, platelet count, and SLEDAI scores were compared between two groups before treatment and 3, 6, and 12 months after delivery.
Three patients in the non-PE group ended in miscarriage while all patients in the PE group were delivered successfully. Eleven successfully delivered fetuses in the two groups were healthy, and the Apgar scores were over 8. The ESR of the PE group was significantly lower than that of the non-PE group at 6 and 12 months after delivery, while there was no statistical difference in ESR between the two groups before treatment and 3 months after delivery. The ESR and urine protein were significantly higher in the non-PE group at months 3, 6, and 12 postpartum. There was a significant decrease in disease activity postpartum in the PE group compared to predelivery disease activity. The change in platelet counts between the two groups significantly increased over time in the PE group, while SLEDAI scores decreased.
The combination of PE and oral prednisone and HCQ is possibly a more effective treatment than oral prednisone and HCQ alone for patients with active SLE during pregnancy. This treatment option reduces pregnancy loss and promotes the patients' postpartum condition to a certain extent.
探讨血浆置换(PE)联合或不联合泼尼松和羟氯喹(HCQ)治疗妊娠合并系统性红斑狼疮(SLE)的临床疗效。
回顾性分析我院收治的 14 例妊娠合并 SLE 患者的临床特征,其中仅接受泼尼松和 HCQ 治疗的患者 7 例(非 PE 组),联合 PE 治疗的患者 7 例(PE 组)。记录 14 例患者的分娩情况。比较两组患者治疗前及产后 3、6、12 个月的红细胞沉降率(ESR)、尿蛋白、血小板计数及 SLEDAI 评分。
非 PE 组 3 例患者流产,PE 组均足月分娩。两组均有 11 例成功分娩的胎儿健康,Apgar 评分均>8 分。PE 组产后 6、12 个月的 ESR 明显低于非 PE 组,而两组治疗前及产后 3 个月的 ESR 无统计学差异。非 PE 组产后 3、6、12 个月 ESR 和尿蛋白均明显高于产后。与产前相比,PE 组产后疾病活动度明显降低。PE 组血小板计数随时间的变化显著增加,SLEDAI 评分降低。
PE 联合口服泼尼松和 HCQ 治疗活动期妊娠合并 SLE 可能优于单纯口服泼尼松和 HCQ,该治疗方案可降低流产率,并在一定程度上改善患者产后病情。